Edmund Pezalla, M.D., MPH, is Aetna’s National Medical Director for Pharmaceutical Policy and Strategy. He is responsible for the integration of pharmacy policy and activities into Aetna’s overall strategy and operations. Dr. Pezalla also serves as the lead clinical spokesperson for Aetna in pharmacy related issues and represents Aetna on industry work groups and conferences.
Dr. Pezalla is Aetna’s leading executive on pharmaceutical development, reimbursement strategy and drug evaluation. He is active on projects with the IOM, CDC and FDA as well as MIT’s Center for Biomedical Innovation.
Dr. Pezalla was an invited expert contributing to the President’s Council of Advisors on Science and Technology report: Propelling Innovation in Drug Discovery, Development and Evaluation. In 2014 Dr. Pezalla served as Aetna’s interim Chief Medical Officer for SEHA, the Qatari National Health Insurance Scheme.
Dr. Pezalla is a graduate of Georgetown University College of Arts and Sciences, and Georgetown University School of Medicine. He holds an MPH from the University of California at Berkeley and was a research fellow and doctoral student in Health Management and Policy at the University of Michigan.
Dr. Pezalla will be speaking at World Anti-Microbial Resistance Congress USA 2016, with a session entitled, “Do antimicrobial development and reimbursement models make sense to payers?” This session will answer the following questions:
- What do payers need from industry to justify the high prices of antimicrobials?
- What are the main uptake limitations of new drugs when it comes to pricing and reimbursement?
- What data is needed to support decision-making?
- Are these models helping with innovation?
To hear from Dr. Edmund Pezalla and more industry experts, attend World Anti-Microbial Resistance Congress USA 2016, held September 8-9 in Washington, DC.